1 jan 2014 ano - Pembrolizumab
Descrição:
Pembrolizumab is approved for advanced melanoma treatment by the FDA. This monoclonal antibody blocks a protein called PD1's activity on immune cells, which increases the strength of the immune response to cancer.
Adicionado na linha do tempo:
Data: